Article Abstract

The importance of PD-L1 diagnostic assay harmonization for the selection of lung cancer immunotherapy

Authors: Juan-Manuel Hernandez-Martinez, Zyanya Lucia Zatarain-Barrón, Andrés F. Cardona, Oscar Arrieta


The introduction of immune checkpoint inhibitors (ICIs), antibodies that target co-inhibitory molecules to improve anti-tumor immune responses, has dramatically changed the therapeutic landscape of several malignancies, particularly that of lung cancer (1,2).